Stock Monitor: American Renal Associates Holdings Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Heska Corp. (NASDAQ: HSKA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=HSKA as the Company's latest news hit the wire. On May 15, 2018, the Company announced that it has signed a licensing agreement with MBio Diagnostics, Inc. ("MBio") for the development of new products and solutions aimed at the animal health market. The financial terms and other details of the agreement were not disclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for American Renal Associates Holdings, Inc. (NYSE: ARA), which also belongs to the Healthcare sector as the Company Heska. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ARA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Heska most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=HSKA

Scope of the Collaboration

This is an exclusive collaboration for multiplex immunoassay tests using MBio's LightDeck® platform. The Companies will jointly develop products by leveraging the strengths of MBio in the area of clinical diagnostics and sample testing and Heska's expertise in veterinary diagnostics.

The MBio Array System utilizes MBio's proprietary LightDeck® technology, which allows for simple, multiplex testing in a compact system. When the MBio Array System is combined with Heska's proprietary reagents, one can get multiplexed, high sensitivity assays directly in the vet clinic. This eliminates the need to send out samples to get a similar result from an expensive reference laboratory. MBio's immunoassay system allows for testing for diverse applications like vector-borne diseases, parasitology, and animal health and wellness. The best part is that the compact, portable, and user-friendly multiplex reader needs very little space and can be used for testing at any place, may it be clinics or animal hospital labs.

Quotes from Management

Commenting on the exclusive collaboration with Heska, Chris Myatt, Chief Executive Officer (CEO) of MBio, said:

"We have made enormous progress advancing our platform technology in recent years, and we are now executing on strategic partnerships that open new high-value opportunities. Recent developments in the veterinary field have emphasized the value of multiplex testing solutions. Our partnership with Heska will provide this high quality of testing directly in the clinic."

Kevin Wilson, CEO of Heska, added:

"MBio's fantastic innovation, when combined with Heska's experience providing gold standard healthcare solutions to the veterinary field, will provide veterinarians and their patients accurate, reliable, best-in-class results, and as we build out the test menu, entirely new classes of point of care testing."

About the MBio Array System

The MBio Array System is a multiplex reader which is portable, user-friendly, and provides lab-quality results within one minute to 20 minutes. The multiplex reader uses low-cost, disposable load-and-go cartridges.

The MBio Array System uses MBio's patented LightDeck® planar waveguide technology. This technology eliminates the process of sample prep and can be customized to detect all key analytes, including proteins, cells, nucleic acids, and small molecules.

About MBio Diagnostics Inc.

Boulder, Colorado-based MBio is a leading Company in the field of rapid, on-the-spot clinical diagnostics and sample testing. The Company uses its patented LightDeck® technology which not only simplifies the test processes but allows simplified manufacturing steps. The testing can be used across Medical, Veterinary, Environmental, Food, and Military industries.

The Company has several patents for its detection system including 8 issued US utility patents and 5 design patents on its core technology, as well as 7 issued international patents in China, Japan, South Africa, and several European countries. The Company has an additional 11 patent applications in prosecution worldwide. The Company's efforts are supported by its team of instrumentation engineers, biological assay scientists, and disposable cartridge developers.

About Heska Corp.

Loveland, Colorado-based Heska is a leading veterinary diagnostics Company that manufactures, develops, and sells advanced veterinary diagnostic and specialty healthcare products. The Company has two main business units, namely (i) Core Companion Animal Health (CCA), and (ii) Other Vaccines, Pharmaceuticals, and Products (OVP). CCA is focused on products for canine and feline use, while OVP is focused on herd animal health. Heska offers a range of complete blood diagnostic solutions including Chemistry, Hematology, Blood Gas & Electrolytes, Immunodiagnostics, Heartworm, and other blood testing. Treatments and testing include Immunotherapy and complete Allergy Solutions.

Stock Performance Snapshot

May 16, 2018 - At Wednesday's closing bell, Heska's stock advanced 6.75%, ending the trading session at $99.74.

Volume traded for the day: 189.44 thousand shares, which was above the 3-month average volume of 96.01 thousand shares.

Stock performance in the last month ? up 25.52%; previous three-month period ? up 65.93%; past twelve-month period ? up 2.29%; and year-to-date - up 24.35%

After yesterday's close, Heska's market cap was at $737.08 million.

Price to Earnings (P/E) ratio was at 55.60.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 0.6% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst. For further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors